Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
After hours: 7 March at 19:56:25 GMT-5 Loading Chart for MRSN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback